Key result
Allograft coronary disease has emerged as a major limitation to long-term heart transplant recipient survival, accounting for the most deaths in patients surviving for more than one year.
Allograft coronary disease is a major limitation to long-term survival in heart transplant recipients, presenting significant diagnostic and therapeutic challenges.
Answers are grounded in this paper and cite their sources.
Underscores allograft coronary disease as a key survival barrier post-transplant; leaves open optimal surveillance and therapy strategies.
Heart transplantation is an accepted therapeutic option for end-stage heart failure, which gained wide acceptance during the early to mid 1980s. Since that time, the ability to diagnose, treat, and sometimes prevent early posttransplant complications, such as acute rejection and opportunistic infections, has improved dramatically. Some remaining challenges in the diagnosis of rejection on endomyocardial biopsy specimens have been discussed previously in this format (Winters GL. Grade 2 cardiac rejection: pathologic and clinical controversies. Pathology Case Rev 1998;3:66–72). As a result of the above advances, allograft coronary disease has emerged as a major limitation to long-term recipient survival and, in many transplant centers, is the single entity which accounts for the most deaths in patients surviving for more than one year. Allograft coronary disease presents considerable challenges for diagnosis and treatment. Intravascular ultrasound has increasingly gained acceptance over angiography for clinical detection of this disease. The concentric intimal proliferation, which selectively involves the allograft vasculature, frequently results in secondary ischemic changes to the myocardium that may be detected on endomyocardial biopsy specimens. Although allograft coronary disease has been well described pathologically, the greatest challenge remains the better understanding of the pathogenesis of this process so that therapy may be specifically targeted and long-term recipient survival becomes routine.
No takes yet. Share an insight, caveat, or question.
Gayle L. Winters (2001) conducted a review in Allograft coronary disease in heart transplant recipients. Allograft coronary disease has emerged as a major limitation to long-term heart transplant recipient survival, accounting for the most deaths in patients surviving for more than one year.
Synapse has enriched 10 related papers. Consider them for comparative context: